Molecular and Cellular Biology, October 2002, p. 6930, Vol. 22, No. 19
0270-7306/02/$04.00+0 DOI: 10.1128/MCB.22.19.6930.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
| AUTHOR'S CORRECTION |
Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Department of Dermatology, and Harvard Skin Disease Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142; Department of Dermatology and The Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114; and Laboratory of Tissue Engineering, Istituto Dermatopatico dell'Immacolata, and San Gallicano Hospital, Rome, Italy
Volume 22, no. 14, p. 5157-5172, 2002. Page 5158, column 1, Materials and Methods, "Culture media and methods," line 5: "Flavin alenine dinucleotide (FAD) medium" should read "FAD medium."
Page 5158, column 1, Materials and Methods, "Culture media and methods," line 9: "10 x 10-10 M" should read "10-10 M."
Page 5171, Acknowledgments, the first paragraph should appear as shown below.
ACKNOWLEDGMENTS
We thank Karl Münger for the p53DD retroviral vector, Denise Galloway for the HPV16 E6E7 retroviral vector, and Jim Koh, Chidi Ngwu, Ed Harlow, Jiri Bartek, Fiona Watt, and Cindy Loomis for providing antibodies. The development of the corneal and conjunctival cell lines was done in collaboration with Ilene Gipson. We thank James Rocco for helpful discussions about p14ARF and are grateful to Jen Benwood, Allan Tulloch, and Denise Long-Woodward for expert technical assistance.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|